The present invention provides a pharmaceutical composition comprising a compound for use in preventing and/or treating infections caused by SARS-CoV2. There is also provided, the use of a pharmaceutical composition comprising a compound for the manufacture of a medicament for the prevention and/or the treatment of infections caused by SARS-CoV-2. Besides that, the present disclosure relates also to a method for inhibiting the production of SARS-CoV2. Provided, a method for virtual screening for such compounds.

The present invention provides a pharmaceutical composition comprising a compound for use in preventing and/or treating infections caused by SARS-CoV2. There is also provided, the use of a pharmaceutical composition comprising a compound for the manufacture of a medicament for the prevention and/or the treatment of infections caused by SARS-CoV-2. Besides that, the present disclosure relates also to a method for inhibiting the production of SARS-CoV2. Provided, a method for virtual screening for such compounds.

A method for producing a mammalian brain protein hydrolysate composition, by providing a mammalian brain protein hydrolysate, adding Zn ions to the mammalian brain protein hydrolysate to form a complex with the Zn ions and the mammalian brain protein hydrolysate, and obtaining the complex with the Zn ions and the mammalian brain protein hydrolysate in a mammalian brain protein hydrolysate composition. A composition with a mammalian brain protein hydrolysate. A nutritional supplement with a mammalian brain protein hydrolysate. A pharmaceutical composition with a mammalian brain protein hydrolysate.

A method for producing a mammalian brain protein hydrolysate composition, by providing a mammalian brain protein hydrolysate, adding Zn ions to the mammalian brain protein hydrolysate to form a complex with the Zn ions and the mammalian brain protein hydrolysate, and obtaining the complex with the Zn ions and the mammalian brain protein hydrolysate in a mammalian brain protein hydrolysate composition. A composition with a mammalian brain protein hydrolysate. A nutritional supplement with a mammalian brain protein hydrolysate. A pharmaceutical composition with a mammalian brain protein hydrolysate.

Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.

Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.

The present application relates to nanoparticles including an antiretroviral drug and chitosan and optionally one or more metal cation, their use for treating viral infections, their process of preparation and the pharmaceutical compositions including the same.

The present application relates to nanoparticles including an antiretroviral drug and chitosan and optionally one or more metal cation, their use for treating viral infections, their process of preparation and the pharmaceutical compositions including the same.

The invention concerns Flavine adenine dinucleotide (FAD) for use in preventing and/or treating cancer. The FAD is favorably encapsulated at least partially in a particle with a vector to improve its absorption and distribution while limiting its destruction, in particular by blood hydrolases. The invention relates to the pharmaceutical field and more specifically to oncology or cancerology.

The invention concerns Flavine adenine dinucleotide (FAD) for use in preventing and/or treating cancer. The FAD is favorably encapsulated at least partially in a particle with a vector to improve its absorption and distribution while limiting its destruction, in particular by blood hydrolases. The invention relates to the pharmaceutical field and more specifically to oncology or cancerology.